Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01678092 · ClinicalTrials.gov registry record · Phase 1
Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01678092 is a Phase 1 study of Atopic Dermatitis that has completed, run by Stanford University. The registered enrollment target is 8 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01678092, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
A phase 1 single center study in which omalizumab is dosed normally (according to the product insert) in subjects with atopic dermatitis.
Conditions Studied
Interventions
- BIOLOGICAL omalizumab
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01678092
The ClinicalTrials.gov registry entry for NCT01678092 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (99% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which omalizumab is the first listed.
NCT01678092 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01678092 about?
NCT01678092 is a clinical study titled "Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis". A phase 1 single center study in which omalizumab is dosed normally (according to the product insert) in subjects with atopic dermatitis.
What is the current status of trial NCT01678092?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2004-05. Estimated completion is 2006-12.
What conditions does trial NCT01678092 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT01678092?
The interventions under investigation include: omalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01678092?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01678092 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.